Purpose Pharmacokinetic considerations in patients who have undergone Roux-en-Y gastric bypass (RYGB) are explored. Summary The prevalence of obesity, especially morbid obesity, has dramatically ...

Utilizing drug properties such as pK a, log P, and drug transporters employed can help practitioners select more appropriate drug therapy for the gastric bypass patient.